Purpose: Continuous epidural analgesia is increasingly used to manage acute and chronic pain. Epidural analgesia affords profound pain relief, and, in certain high-risk patients, may decrease morbidity, mortality, and treatment costs. However, some investigators have reported that this form of treatment has resulted in the development of epidural abscesses.
Some investigators have described the antimicrobial properties of local anesthetic agents that have been used in continuous epidural analgesia. It has been suggested that the use of these agents may significantly alter the microbial population.
The purpose of this study was to determine the risk of growth of
Staphylococcus epidermidis in local anesthetics commonly used in clinical practice, specifically 0.5%, 1%, and 2% lidocaine; 0.125%, 0.25%, and 0.5% bupivacaine; and 0.5%, 1%, and 2% mepivacaine.
Methods: Diluted bacterial suspension of
Staphylococcus epidermidis was added to the 0.9% sterile nonbacteriostatic saline or the different local anesthetics. After the organisms were added, a sample from each vial was put into one plate of trypicase soy agar at 0, 0.5, 2 and 4 h intervals for a total of three plates per solution per sampling period. All were stored and incubated at 37˚C in an atmosphere of 5% CO
2 for 24 h. Each plate medium was read and the number of colony-forming units (CFUs) was counted and recorded by the same investigator.
Results: The number of CFUs declined in proportion to time incubated in all three anesthetics, indicating that all the local anesthetics inhibited the growth of
Staphylococcus epidermidis, with the antimicrobial activity of bupivacaine being strongest, followed by lidocaine and then mepivacaine. Effects were proportional to concentration and time: higher concentrations and longer times led to a reduced number of CFUs.
Conclusions: We conclude that lidocaine, mepivacaine and bupivacaine all inhibit the growth of
Staphylococcus epidermidis.
抄録全体を表示